Bradley Kozar to Bring Market Access Expertise to RxC International as Strategy Partner

Bradley Kozar RxC International.jpg

FOR IMMEDIATE RELEASE

Date September 6, 2017

MORRISTOWN, NJ, RxC International, a premier life sciences management consulting firm, announced today that Bradley K. Kozar has joined the firm as a Strategy Partner. Brad is a payer strategy and market access consulting executive with significant consulting/agency and pharmaceutical industry experience. “Brad is a leading expert in managed markets - he has led many successful biopharma product launches and has been instrumental in helping his clients achieve more favorable market access through better formulary placement and reimbursement.  We are excited to have Brad joining us to provide our clients with a more integrated offering by addressing market access within our core services of corporate strategy, new product strategy and commercial excellence,” said Subbarao Jayanthi, Managing Partner of RxC International.

Prior to joining RxC International, Brad founded MediMedia Managed Markets, LLC, which he led for 16 years before a successful divestiture of the company (now owned by ICON plc).  Brad successfully leveraged his extensive strategy consulting experience at Charles River Associates where he served as a payer strategist and at NucleusX where he served as Global Head of Market Access and HEOR.  Brad also gained significant biopharma industry experience early in his career at Marion Labs and Ortho Biotech/Johnson & Johnson.

Brad has deep expertise across multiple therapeutic areas including biologics, oncology, and specialty products, as well as a strong understanding of current and evolving healthcare delivery models including Commercial Managed Care, Pharmacy Benefit Managers (PBMs), Government (i.e. Medicare Part D, Medicaid, VAs/Tricare), Accountable Care Organizations (ACOs), Health Exchanges, Long Term Care/Home Health, and Employers.

Throughout his career, Brad was instrumental to the success of a number of blockbuster drugs and biopharmaceutical/specialty products while ensuring the highest level of client focus and satisfaction.  “I’m very excited about joining RxC International to add market access to their expertise and provide clients with a more complete suite of critically important services. Following product approval, market access and reimbursement often are the most important determinants of product uptake, revenue, and life cycle success,” said Kozar.

Brad serves on boards for several nonprofit organizations, has served on the Industry Advisory Board of the Academy of Managed Care Pharmacy (AMCP), and has frequently been a speaker at conferences on managed care and market access. He has moderated more than 800 customer policy, research, and advisory board meetings as well as served as a panel moderator and trainer.

Brad holds a degree in Communication from the University of Toledo, where he has continued his involvement as a member of the Alumni Board of Trustees and other committees within the university campus (which includes a Medical School, Pharmacy School, Business School, etc.).

###

ABOUT RXC INTERNATIONAL

RxC International is a premier life sciences management consulting firm. RxC collaborates with clients to identify and develop growth opportunities. The firm leverages consulting partners and advisers to combine strategic and operational expertise to bring multiple perspectives to every engagement. The firm has deep expertise in corporate strategy, new product strategy, and commercial excellence. Clients include leading pharmaceutical, biotechnology, and medical technology companies around the world. The firm also supports private equity and venture capital firms on strategic transactions. The firm’s corporate headquarters is located in Morristown, New Jersey, and it has offices in Massachusetts and California. Additional information about RxC International can be found at www.RxCInternational.com.

CONTACTS

RxC International

Frank Koos, 855-792-7920

FKoos@RxCInternational.com

Philip Vorhies to Bring Added New Product Strategy and Commercial Expertise to RxC International as Strategy Partner

RxC Philip Vorhies

FOR IMMEDIATE RELEASE

June 21, 2017

MORRISTOWN, NJ, RxC International, a premier life sciences management consulting firm, announced today that Philip Vorhies has joined the firm as a Strategy Partner. Philip is an experienced strategy and operations consulting executive with over 20 years of biopharmaceutical industry experience.  “Philip has an excellent track record of value creation for life sciences clients. He is truly passionate about helping his clients succeed.  He has led several successful pharma and biotech product launches and been instrumental in building highly productive consulting teams.  We are excited to have Philip on board as we continue to strengthen our management team,” said Subbarao Jayanthi, Managing Partner of RxC International.

Philip has deep expertise in the areas of new product strategy and commercial excellence.  He has executed several successful engagements in the areas of product launch strategy, brand and portfolio strategy, and life cycle planning.  “Philip will be responsible for leading our West Coast practice at RxC International,” said Jayanthi.

Prior to joining RxC, Philip held leadership positions at Cello Health BioConsulting and Campbell Alliance where he was responsible for leading the East Coast strategic consulting business.  Philip has expertise across multiple therapeutic areas including rare diseases, oncology, and specialty biopharma.  Throughout his career, Philip has worked with clients ranging from early-stage to world leading companies to identify growth opportunities.  “I look forward to working with RxC as they have an innovative business model for client engagements and provide tremendous value compared to traditional management consulting firms. RxC also has strong IP and delivers actionable insights that allow their clients to implement and evolve as their business changes,” said Vorhies.

Philip holds a Bachelor of Science in Physiology and Neuroscience from the University of California, San Diego.  He also earned an MBA in Strategy and Finance with Dean’s List and Beta Gamma Sigma distinctions from the Marshall School of Business at the University of Southern California.

###

About RxC International

RxC International is a premier life sciences management consulting firm. RxC collaborates with clients to identify and develop growth opportunities. The firm leverages consulting partners and advisers to combine strategic and operational expertise to bring multiple perspectives to every engagement. The firm has deep expertise in corporate strategy, new product strategy, and commercial excellence. Clients include leading pharmaceutical, biotechnology, and medical technology companies around the world. The firm also supports private equity and venture capital firms on strategic transactions. The firm’s corporate headquarters is located in Morristown, New Jersey, and it has offices in Massachusetts and California. Additional information about RxC International can be found at www.RxCinternational.com.

Contacts

RxC International

Frank Koos, 855-792-7920

FKoos@RxCInternational.com

Biopharma Leader James Hoyes Joins RxC International as Executive Partner

MORRISTOWN, N.J.--(BUSINESS WIRE)--RxC International, a premier life sciences management consulting firm, announced today that James Hoyes has joined the firm as an executive partner. Hoyes had been working with RxC International as a senior advisor since 2014. He has a long track record of creating strategies and driving exceptional performance in the life sciences sector.

In addition to providing advisory services to RxC International clients, Hoyes will focus on corporate development initiatives in the life sciences sector and the implementation of key strategic initiatives designed to scale up the firm’s global operations. He will be based in Cambridge, Massachusetts.

RxC International Managing Partner Subbarao Jayanthi said, “Jim’s addition represents another milestone in the expansion of our business. He has an outstanding track record as a leader in the life sciences sector, and his deep strategic and executive leadership expertise will be invaluable to our clients.”

Prior to joining RxC International, Hoyes served as President of EMD Serono, leading the company in consistent double-digit revenue gains. Prior to EMD Serono, Hoyes held leadership positions with several leading biopharma companies, including chief commercial officer at Serono, vice president of marketing at Elan, vice president of managed markets at Sanofi, and senior director of cardiovascular and strategic marketing at Sanofi-Synthélabo.

RxC International Executive Partner James Hoyes said, “Today, both the opportunities and challenges for biopharma companies are many – the growing complexity and increasing interdependencies require the right perspective and a steady hand. Actually, realizing the value of an unmet need is not always easy. RxC International helps clients navigate the competitive landscape in order to maximize value and build a sustainable position in a given therapeutic area. The business model of RxC International – working closely as partners with clients and developing a compelling strategy and a clear plan to execute – resonates well with our growing list of clients. I am pleased and excited to join the RxC International team to focus on value and growth creation for clients.”

Hoyes holds a bachelor of science in biology from the Pennsylvania State University. He has served on the boards of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO). He currently serves as a board member of MassBIO.

About RxC International

RxC International is a premier life sciences management consulting firm. RxC collaborates with clients to identify and develop growth opportunities. The firm leverages consulting partners and advisers to combine strategic and operational expertise to bring multiple perspectives to every engagement. The firm has deep expertise in corporate strategy, new product planning and commercial excellence. Clients include leading pharmaceutical, biotechnology, and medical technology companies around the world. The firm also supports private equity and venture capital firms on strategic transactions. The firm’s corporate headquarters is located in Morristown, New Jersey, and it has offices in Massachusetts and California. Additional information about RxC International can be found at www.RxCinternational.com.

Contacts

RxC International
Subbarao Jayanthi, 855-792-7920
Info@RxCInternational.com

RxC International to Lead Gene Therapy Panel at NewYorkBIO Annual Conference

MORRISTOWN, N.J.--(BUSINESS WIRE)--RxC International today announced that it has been selected by NewYorkBIO, New York State’s life science trade association, to lead a panel on gene therapy at its annual conference in New York City, May 11 - 12, 2016. The panel will be led by RxC International Senior Partner Richard Tinsley.

“We are excited to bring a diverse group of thought leaders together to explore the fast-emerging gene therapy segment of the life sciences industry,” said Subbarao Jayanthi, managing partner of RxC International.

RxC International Senior Partner Richard Tinsley said, “Although there are only four gene therapy products approved across the major developed markets – North America, the EU, and Japan – there are nearly 1,000 active gene therapy programs in development across a wide range of therapy areas and disease states. Gene therapy programs face a range of unique R&D, commercialization, funding, legal and ethical issues. Our panel will explore some of the hurdles faced by life science leaders working with this promising therapeutic class.”

The RxC International gene therapy panel members will include:

  • Sean Ainsworth, CEO, RetroSense
  • Constance Bagley, Senior Research Scholar at Yale Law School, consultant, and author
  • Jim Dentzer, Chief Financial and Chief Administrative Officer at Curis
  • Mark Scheideler, Founder, HumanFirst Therapeutics

“We are pleased to have RxC International’s participation at the conference given its focus as an organization on this topic and the growing interest across the industry in this therapy area,” said NewYorkBIO Executive Director Nathan Tinker.

About New York Biotechnology Association, Inc.

New York Biotechnology Association, Inc. (NewYorkBIO) supports the development and growth of New York State's life science industry and serves its members and the life science community by providing a network for public policy, industry advocacy, and community development. For over 25 years, NewYorkBIO and its 250+ member companies have been at the forefront of developing, nurturing, and expanding New York’s life science industry. For more information about NewYorkBIO and the conference, see: www.newyorkbio.org.

About RxC International

RxC International is a premier life sciences management consulting firm. The RxC team collaborates with clients to identify and develop growth opportunities. RxC leverages consulting partners and advisers to combine strategic and operational expertise to bring multiple perspectives to every engagement. RxC has deep expertise in corporate strategy, new product planning and commercial excellence.

RxC International clients include global pharmaceutical and biotechnology companies as well as other specialty life sciences companies such as vaccine, biosimilar, diagnostic, and medical device companies. RxC has offices in New Jersey, Massachusetts, and California. Additional information about RxC International can be found at www.rxcinternational.com.

Contacts

RxC International
Frank Koos, 855-792-7920
Head of Business Development
Info@RxCInternational.com

RxC International’s Richard J. Tinsley to Present at PBIRG Annual General Meeting

MORRISTOWN, New Jersey – May 14, 2015 – RxC International today announced that Richard J. Tinsley, MBA, MEd, a senior partner in the firm, will present at this year’s PBIRG Annual General Meeting, which will take place May 17-20, 2015, in New Orleans. Tinsley will participate in a panel to discuss the future of healthcare. This year’s PBIRG Annual General Meeting will cover a wide range of topics on the future of healthcare. 

“The healthcare environment is changing rapidly, and stakeholders are shifting focus towards increasing quality of care while reducing costs,” said Subbarao Jayanthi, Managing Partner at RxC International. “Rich has been advising life sciences clients on how best to navigate through the evolving healthcare environment, and he’s considered an expert in this area,” added Jayanthi.

Tinsley plans to address several important developments in the U.S. healthcare system, including:

  • the need for holistic and targeted approaches to manage the care continuum 
  • the need for stakeholder (provider, payer, and patient) collaboration for long-term value creation
  • the role of evolving ACOs in enhancing the quality of healthcare
  • balancing health outcomes and economics
  • the need for integrated delivery networks to effectively manage information

Tinsley was recently appointed to the Massachusetts Board of Pharmacy, and he has previously held leadership roles at Bain & Company and Putnam Associates. Tinsley holds an undergraduate degree in finance from Wharton at University of Pennsylvania as well as an MBA and Masters in Education from Stanford University. He joined RxC International as a senior partner in March of 2015.

About RxC International

RxC International is a global life sciences management consulting firm specializing in corporate strategy, new product development, and commercialization. RxC International brings strategic and operational expertise to its clients via a unique consulting delivery model. RxC International clients include leading pharmaceutical and biotechnology companies as well as other specialty life sciences companies such as vaccines, biosimilars, generics, and medical device companies. Based in Morristown, New Jersey, RxC International services clients worldwide.  Additional information about RxC International can be found at www.rxcinternational.com

Source: RxC International.   For more information, contact Frank Koos, Head of Business Development at RxC International at 855-792-7920 or at Info@RxCInternational.com.

Richard J. Tinsley Joins RxC International as a Senior Partner

MORRISTOWN, New Jersey – February 25, 2015 – RxC International today announced that Richard J. Tinsley, MBA, MEd, has joined the firm as a senior partner. RxC International is a life sciences management consulting firm specializing in corporate strategy, new product development, and commercialization.

“We are delighted to announce that Rich has joined RxC International,” said RxC International Managing Partner Subbarao Jayanthi. “Rich’s tremendous expertise in the life sciences industry further enhances the RxC International team and helps to strengthen our presence in the Boston area. It’s an exciting time for us to have Rich on board as we continue to expand our business.”  

Tinsley brings more than 20 years of strategy consulting experience in the life sciences industry to his role as a senior partner with RxC International. Prior to joining RxC International, Tinsley consulted for several leading life science companies, successfully crafting and implementing corporate, commercialization, and life cycle management strategies. Tinsley recently served on the board of directors of the Massachusetts Board of Registration in Pharmacy, and he has previously held leadership roles at Bain & Company and Putnam Associates. Tinsley holds an undergraduate degree in finance from Wharton at University of Pennsylvania and an MBA from Stanford University.

About RxC International

RxC International is a life sciences management consulting firm specializing in corporate strategy, new product development, and commercialization. RxC International brings strategic and operational expertise to its clients via a unique consulting delivery model that delivers exceptional value. RxC International clients include leading pharmaceutical and biotechnology companies as well as specialty life sciences companies such as vaccines, biosimilars, medical devices, etc.  Based in Morristown, New Jersey, RxC International services clients all over the world.  Additional information about RxC International can be found at www.RxCInternational.com. 

Source: RxC International

For more information, contact Frank Koos, Head of Business Development of RxC International at 855-792-7920 or at Info@RxCInternational.com.

RxCommercial Research International Launches its 2nd Edition of its Successful book on Commercialization of BioPharmaceutical Products in the USA

Morris Plains, New Jersey—RxCommercial Research International has announced the release of the second edition of its successful Practical Guide on commercializing pharmaceutical products in the USA.  Pharmaceutical and Biotechnology companies produce innovative life-saving and life-enhancing medicines for patients. The discovery, development, manufacturing, distribution, and commercialization of a biopharmaceutical product are highly complex processes and they get further compounded due to the regulatory nature of the industry. This book not only offers insights into all areas of the product value chain but also shows strategic choices that companies have to deal with at each and every stage of the commercialization process.

In the current US value-driven healthcare environment, product commercialization requires developing a compelling outcomes-driven value story and selling it to diverse stakeholder groups such as patients, providers, payers, and policy makers to ensure product adoption. The commercial success of a product is critical in maximizing a product’s potential and as well as the shareholder return. 

According to RxCommercial’s research team, anyone involved in commercialization activities in the pharmaceutical and biotechnology industry could greatly benefit from this guide.  This guide offers valuable frameworks that pharmaceutical and biotechnology professionals could take advantage of every day as they strive to achieve differentiated positioning for their products in this value-driven competitive healthcare environment. The first edition of this Practical Guide is being used by some of the Top 20 global biopharmaceutical companies. Significant enhancements have been made to make this guide more user-friendly.  This Practical Guide is currently available in most countries in North America, South America, Europe, and Asia via strategic partners. 

For additional information on this publications, please click here.

About RxC Corporate Research

RxC Corporate Research is a division of RxC International which is a global life sciences management consulting firm.  The corporate research focuses on offering “innovative and practical insights into development and commercialization of life sciences products.  In addition to that the firm offers insights into investing into life sciences products as well. The firm develops solutions to empower professionals and investors in the pharmaceutical and biotechnology sectors. The company has a global presence with the corporate headquarters in New Jersey, USA.